[{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarck Announces, Phase 2a Clinical Trial Results of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO-11006","moa":"MARCKS protein","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acquist Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Acquist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acquist Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biomarck Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO-11006","moa":"MARCKS protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biomarck Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Biomarck Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomarck Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biomarck Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Biomarck Clinical and Preclinical Studies of BIO-11006 in ARDS to be Presented at the 2021 ARDS Drug Development Summit","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"BIO-11006","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biomarck Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomarck Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomarck Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for BIO-11006

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : In the Phase 2 clinical study, rapid and faster improvements in oxygenation were observed in patients receiving BIO-11006 compared to placebo (half normal saline), together with decreases in pro-inflammatory cytokines.

                          Brand Name : BIO-11006

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          July 07, 2021

                          Lead Product(s) : BIO-11006

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Data to be presented showed that inhaled BIO-11006 decreases metastasis and tumor progression, and increases the overall response rate and survival in patients with advanced NSCLC.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 01, 2020

                          Lead Product(s) : BIO-11006

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : BIO-11006 demonstrated safety and a 43 percent reduction in all-cause mortality at 28 days in ARDS.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 23, 2020

                          Lead Product(s) : BIO-11006

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank